Pneumococcal disease is responsible for approximately 1.6 million deaths worldwide each year, of which nearly 50% are in children under 5 years of age, and mainly in third world countries.
Pneumococcal disease is responsible for approximately 1.6 million deaths worldwide each year. (Source: Plenglish)
Cuba has resumed clinical trials of its vaccine candidate Chemistry-Vioresearched and developed by scientists from the Finlay Institute of Vaccines (IFV).
This preparation is expected to provide protection against the seven most infectious serotypes and with a high global prevalence of pneumococcal infections.
The Granma Daily, the mouthpiece of Cuban Communist Partysaid scientists from IFV and BioCubaFarma Pharmaceutical and Biotechnology Group’s Business Group have resumed clinical trials of Quimi-Vio, which had been halted previously to prioritize vaccine development. prevent COVID-19, and complete the registration dossier to submit to the National Management Authority.
According to IFV Deputy Director Yuri Valdés Balbín, Quimi-Vio is like seven vaccines developed in one and will help fight certain serotypes of pneumococcal disease, which causes most pneumonia and meningitis caused by bacteria in children, as well as blood infections, otitis media, sinusitis, and bronchitis.
Valdés Balbín said that in previous trials, the Quimi-Vio vaccine had shown remarkable effectiveness and helped increase immunity against pneumococcal. This preparation has also been shown to be safe and cause only mild local side effects.
Once approved, the Quimi-Vio vaccine will be applied first to a population of 1 to 5 years old and then to children from birth to 6 months of age.
Theo BioCubaFarmaResearch on this vaccine candidate has been prioritized for development since 2006 in the hope that it will be the most complex preventive drug studied by Cuba to date.
During 7 years of clinical research, scientists performed more than 300 analytical controls and numerous surveillance, economic, and impact studies.
Sick pneumococci It is a dangerous disease with a very high mortality rate. According to medical experts, pneumococcus is a common bacterium in the pharynx of adults and children, causing dangerous diseases and leaving many serious sequelae even after recovery.
The World Health Organization (WHO) estimates pneumococcal causes about 1.6 million deaths worldwide each year, of which nearly 50% are in children under 5 years of age, and mainly in third world country.
The number of children who die from pneumococcal infections accounts for about 11% of all deaths of children under 5 years of age. Bacteria are already resistant to many commonly used antibiotics, making treatment very expensive and difficult.